Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Design of an Ara h 2 hypoallergen from conformational epitopes (in EN)

Journal Article · · Clinical & Experimental Allergy
DOI:https://doi.org/10.1111/cea.14433· OSTI ID:2582705
Abstract Introduction

Adverse reactions are relatively common during peanut oral immunotherapy. To reduce the risk to the patient, some researchers have proposed modifying the allergen to reduce IgE reactivity, creating a putative hypoallergen. Analysis of recently cloned human IgG from patients treated with peanut immunotherapy suggested that there are three common conformational epitopes for the major peanut allergen Ara h 2. We sought to test if structural information on these epitopes could indicate mutagenesis targets for designing a hypoallergen and evaluated the reduction in IgE binding via immunochemistry and a mouse model of passive cutaneous anaphylaxis (PCA).

Methods

X‐ray crystallography characterized the conformational epitopes in detail, followed by mutational analysis of key residues to modify monoclonal antibody (mAb) and serum IgE binding, assessed by ELISA and biolayer interferometry. A designed Ara h 2 hypoallergen was tested for reduced vascularization in mouse PCA experiments using pooled peanut allergic patient serum.

Results

A ternary crystal structure of Ara h 2 in complex with patient antibodies 13T1 and 13T5 was determined. Site‐specific mutants were designed that reduced 13T1, 13T5, and 22S1 mAbs binding by orders of magnitude. By combining designed mutations from the three major conformational bins, a hexamutant (Ara h 2 E46R, E89R, E97R, E114R, Q146A, R147E) was created that reduced IgE binding in serum from allergic patients. Further, in the PCA model where mice were primed with peanut allergic patient serum, reactivity upon allergen challenge was significantly decreased using the hexamutant.

Conclusion

These studies demonstrate that prior knowledge of common conformational epitopes can be used to engineer reduced IgE reactivity, an important first step in hypoallergen design.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC02-06CH11357
OSTI ID:
2582705
Journal Information:
Clinical & Experimental Allergy, Journal Name: Clinical & Experimental Allergy Journal Issue: 1 Vol. 54; ISSN 0954-7894
Country of Publication:
United States
Language:
EN

Similar Records

Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy
Journal Article · Mon Jan 16 19:00:00 EST 2023 · Journal of Clinical Investigation · OSTI ID:2423466

Molecular Determinants for Antibody Binding on Group 1 House Dust Mite Allergens
Journal Article · Wed Jul 11 00:00:00 EDT 2012 · J. Biol. Chem. · OSTI ID:1038298

Related Subjects